Improving ovarian cancer treatment by targeting a specific protein complex
Targeting PP4 to improve ovarian cancer response to immunotherapy
This study is looking at how a protein called PP4 might help make immunotherapy work better for people with high-grade serous ovarian cancer, especially since this type of cancer often doesn't respond well to chemotherapy. The goal is to find out how problems with the way cells repair DNA can boost the immune system's ability to fight tumors, which could lead to better treatment options for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project ID | NIH-10898736 on NIH RePORTER |
What this research studies
This research investigates how targeting the PP4 protein complex can enhance the effectiveness of immunotherapy in treating high-grade serous ovarian cancer, which is often resistant to chemotherapy. The study aims to understand how deficiencies in the DNA damage response can increase the immune response against tumors, potentially leading to better treatment outcomes. By exploring the role of PP4 in tumor immunogenicity and the recruitment of immune cells, the research seeks to develop new therapeutic strategies that could improve responses to existing cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, particularly those who have not responded well to chemotherapy.
Not a fit: Patients with early-stage ovarian cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for women with chemo-resistant ovarian cancer.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy responses by targeting similar pathways, indicating potential for success in this approach.
Where this research is happening
Scottsdale, United States
- Mayo Clinic Arizona — Scottsdale, United States (Active)
Researchers
- Principal investigator: Curtis, Marion — Mayo Clinic Arizona
- Study coordinator: Curtis, Marion
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.